

1 **Comprehensive analysis of immune responses in CLL patients after heterologous**  
2 **COVID-19 vaccination**

3

4 **Running title:** Immune response in vaccinated CLL patients

5

6 Hye Kyung Lee<sup>1,\*</sup>, Manuela A. Hoechstetter<sup>2,\*</sup>, Maïke Buchner<sup>3,4,\*</sup>, Trang Thu Pham<sup>2</sup>,  
7 Jin Won Huh<sup>5</sup>, Katharina Müller<sup>6,7</sup>, Sabine Zange<sup>6,7</sup>, Heiner von Buttlar<sup>6,7</sup>, Philipp Gïrl<sup>6,7</sup>,  
8 Roman Wölfel<sup>6,7</sup>, Lisa Brandmeier<sup>3</sup>, Lisa Pfeuffer<sup>3</sup>, Priscilla A. Furth<sup>8</sup>,  
9 Clemens-Martin Wendtner<sup>2,#</sup> and Lothar Hennighausen<sup>1,#</sup>

10

11 <sup>1</sup>National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of  
12 Health, Bethesda, MD 20892, USA.

13 <sup>2</sup>Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University  
14 (LMU), Munich, Germany.

15 <sup>3</sup>Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical  
16 University of Munich, Munich, Germany.

17 <sup>4</sup>TranslaTUM - Central Institute for Translational Cancer Research, Technische  
18 Universität München, 81675 Munich, Germany.

19 <sup>5</sup>Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University  
20 of Ulsan College of Medicine, Seoul, Korea.

21 <sup>6</sup>Bundeswehr Institute of Microbiology, Munich, Germany

22 <sup>7</sup>German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany

23 <sup>8</sup>Departments of Oncology & Medicine, Georgetown University, Washington, DC, USA.

24

25 \* co-first authors

26 # co-senior authors

27

28 Correspondence: LH ([lotharh@nih.gov](mailto:lotharh@nih.gov)) and CMW ([clemens.wendtner@muenchen-  
30 klinik.de](mailto:clemens.wendtner@muenchen-<br/>29 klinik.de))

30

31

## 32 **Abstract**

33 Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors  
34 and anti-CD20 antibodies exhibit low humoral response rate (RR) following SARS-CoV-  
35 2 vaccination. To investigate the relationship between the initial transcriptional response  
36 to vaccination with ensuing B and T cell immune responses, we performed a  
37 comprehensive immune transcriptome analysis flanked by antibody and T cell assays in  
38 peripheral blood prospectively collected from 15 CLL/SLL patients vaccinated with  
39 heterologous BNT162b2/ChAdOx1 with follow up at a single institution. The two-dose  
40 antibody RR was 40% increasing to 53% after booster. Patients on BTKi, venetoclax ±  
41 anti-CD20 antibody within 12 months of vaccination responded less well than those under  
42 BTKi alone. The two-dose T cell RR was 80% increasing to 93% after booster.  
43 Transcriptome studies revealed that seven patients showed interferon-mediated signaling  
44 activation within 2 days and one at 7 days after vaccination. Increasing counts of COVID-  
45 19 specific IGHV genes correlated with B-cell reconstitution and improved humoral RR.  
46 T cell responses in CLL patients appeared after vaccination regardless of treatment  
47 status. A higher humoral RR was associated with BTKi treatment and B-cell  
48 reconstitution. Boosting was particularly effective when intrinsic immune status was  
49 improved by CLL-treatment.

50

## 51 **Introduction**

52 Patients with chronic lymphocytic leukemia (CLL) are considered high-risk for severe  
53 COVID-19 infection, mainly due to their complex underlying immunodeficiency and  
54 inadequate immune response to infections.<sup>1-3</sup> They not only suffer from immune  
55 dysregulation by the disease itself, but their immune system is further disrupted by  
56 treatment-related effects.<sup>4-6</sup> Patients, who are heavily pre-treated with  
57 chemoimmunotherapy, exposed to anti-CD20 antibody or treated actively with B-cell  
58 pathway inhibitors, experience suboptimal antibody response to COVID-19 vaccination  
59 compared to CLL treatment-naïve.<sup>7-13</sup> Robust data on immunogenicity of 2-dose  
60 homologous or heterologous BNT162b2/ChAdOx1 vaccine schedules in leukemia  
61 patients have demonstrated an enhanced humoral and/or cellular immune response.<sup>14,15</sup>  
62 Heterologous vaccine schedules also enhance humoral response in individuals without

63 hematological disease.<sup>16,17</sup> The European Medicines Agency (EMA) and the European  
64 Centre for Disease Prevention and Control (ECDC) discussed potential benefits of  
65 heterologous regimens in 2021.<sup>18</sup>

66 While CLL patients who received their last treatment within 12 months preceding  
67 standard vaccination program demonstrate low response rates, vaccine response rates  
68 increase in seronegative, actively treated patients following boosting.<sup>14,19</sup> In addition,  
69 potential protection against COVID-19 infection provided by T cells, even in the absence  
70 of a humoral response, is of particular clinical interest.<sup>20,21</sup> T cell activation with release  
71 of IFN- $\gamma$  by SARS-CoV-2 is associated with mild disease and viral clearance.<sup>21,22</sup> T cell  
72 mediated immune responses are reported in patients with lymphoid malignancies in the  
73 absence of a humoral response.<sup>23</sup> However, in a mixed group of cancer patients, they  
74 were documented more commonly in combination with a humoral response.<sup>24</sup>

75 Early responses to vaccination are elevated levels of interferons and other  
76 cytokines, which activate the JAK/STAT signaling pathway and induce expression of  
77 immediate and innate response genes. We have used RNA-seq of peripheral immune  
78 cells to identify the innate immune response of healthy individuals receiving the standard  
79 homologous BNT162b2<sup>25</sup> or a heterologous ChAdOx1/BNT162b2<sup>17</sup> regimen. Specific  
80 genetic pathways are differentially activated within the first two days after vaccination and  
81 more prominently in the heterologous cohort. However, there are no reports in the  
82 literature on the immune transcriptomic response in CLL patients receiving COVID-19  
83 vaccines.

84 The utility of heterologous vaccination regimens for improving immune response  
85 in immune compromised patients continues to be deliberated.<sup>26,27</sup> To add to this important  
86 discussion, here we provide a comprehensive transcriptome analysis of peripheral  
87 immune cells from CLL patients who received heterologous ChAdOx1/BNT162b2  
88 vaccination and monitored their innate and humoral immune response until four months  
89 following third vaccination in combination with detailed discussion of disease-status,  
90 treatment regimens, and response to COVID-19 infection during follow-up.

91

## 92 **Methods**

### 93 **Ethical approval**

94 Ethical approval (#20-225) to conduct this analysis was granted by the institutional review  
95 board of the Ludwig-Maximilian University (LMU), Munich as the responsible ethics  
96 committee. Written informed consent was obtained from the study participants.

97

### 98 **Study population, study design and recruitment**

99 From June 2021 through July 2021, 15 patients diagnosed with CLL/SLL between 2003  
100 and 2021 were recruited in a single institution (Department of Hematology and Infectious  
101 Diseases, Munich Clinic, Munich Schwabing, Germany), per recommendation of booster  
102 vaccination by the Standing Committee on Vaccination (STIKO) at the Robert Koch  
103 Institute in Germany. After providing written informed consent for data collection, five  
104 seronegative patients received a third (3-dose) after standard 2-dose homologous  
105 vaccination of BNT162b2 or ChAdOx1. All were heavily pretreated (103, 104) or recently  
106 treated with anti-CD20 mAbs (105, 106) or a BTK inhibitor (107). In addition, ten patients  
107 (2-dose) with different CLL disease and treatment status (201 to 213), half of whom were  
108 seropositive after prime dose of ChAdOx1, received a second homologous or  
109 heterologous dose. At the time of vaccination 14 of 15 patients did not have a history of  
110 COVID-19 infection. Between October 2021 and December 2021, all ten patients of 2-  
111 dose received a third BNT162b2 dose. Antibody response and incidence and outcome of  
112 COVID-19 infections were recorded per routine CLL management. Four patients had a  
113 breakthrough COVID-19 infection with Omicron variant around six months after the third  
114 vaccination, all with mild symptoms. One patient received antiviral treatment with  
115 molnupiravir. Patient #209 had an undiagnosed infection in January 2020, confirmed by  
116 anti-SARS-CoV-2 nucleocapsid IgG antibodies in follow-up.

117

### 118 **Stimulation of lymphocytes and detection of IFN- $\gamma$**

119 For lymphocyte stimulation studies, heparinized blood samples were transported within  
120 four hours of collection to the laboratory. 1mL sample was then transferred to three  
121 QuantiFERON (QFN) ® SARS-CoV-2 (Qiagen) SARS-CoV-2 blood collection tubes  
122 (Sars-CoV-2 specific antigens AGI, AGII, AGIII). After 24 hours of stimulation, plasma  
123 from the stimulated samples was used for the detection Interferon gamma (IFN- $\gamma$ ).

124 Detection was carried using the QuantiFERON® ELISA Human IFN- $\gamma$  (Qiagen). Detected  
125 IFN- $\gamma$  level >0.1 IU/ml is evaluated as positive response.

126

### 127 **SARS-CoV-2 antibody ELISA**

128 End-point binding IgG levels to the S1 domain of the spike protein of SARS-CoV-2 were  
129 measured using the semi-quantitative Anti-SARS-CoV-2 ELISA IgG (EUROIMMUN,  
130 Lübeck), according to the manufacturer's instructions. Positive responses included both  
131 IgG ratio  $\geq 1.1$  and borderline values IgG  $\geq 0.8$  to  $<1.0$ . Negative responses were IgG  
132 ratio  $< 0.8$ . In addition, Quantitative Anti-SARS-CoV-2 ELISA IgG measurement (Atellica  
133 IM SARS-CoV-2 IgG, Siemens) was performed with positive response  $\geq 21.8$  Binding  
134 Antibody Unit/ml (BAU/ml) and negative  $< 21.8$  BAU/ml.

135

### 136 **Virus Neutralization Test**

137 SARS-CoV-2 (strain MUC IMB-1, clade B1) neutralizing antibody titers were determined  
138 as previously described<sup>28</sup>, including positive and negative controls. Heat-inactivated  
139 serum samples in duplicates, including positive and negative control samples, were  
140 serially diluted in 96-well tissue culture plates starting at 1:5 to a maximum of 1:640. Virus  
141 stocks (50 TCID<sub>50</sub>/50  $\mu$ l) were prepared and stored at -80 °C until further use. Virus was  
142 pre-incubated (1 h, 37 °C) with diluted serum samples before Vero E6 cells ( $1 \times 10^4$  cells/50  
143  $\mu$ l) were added. After 72 h (37 °C), supernatants were discarded and wells were fixed  
144 (13% formalin/PBS) and stained (crystal violet, 0.1%). The neutralizing antibody titer  
145 corresponded to the reciprocal of the highest serum dilution showing complete inhibition  
146 cytopathic effect (CPE).

147

### 148 **Flow Cytometry**

149 Cells were stained with fluorochrome-labeled antibodies to manufacturer information  
150 (Staining 1: CD19 PE-Cy7 and CD5 APC; Staining 2: CD3 FITC, CD4 APC-Cy7, CD8  
151 Amcyan, PD1 PE-Cy7, CD25 PE, CD62L APC; staining 3: CD11c PE, CD14 APC-Cy7,  
152 HLA-DR PE-Cy7, CD56 PerCP710, all Biolegend). To block free Fc receptors human Fc  
153 Receptor Binding Inhibitor Polyclonal Antibody (eBioscience) were added 10 min prior to  
154 labeled antibodies. Dead cells were excluded by DAPI (1  $\mu$ g/ml) (Sigma Aldrich) staining.

155 Flow cytometric analysis was performed using a FACS Canto II cytometer (BD  
156 Bioscience). Data was analyzed with the FlowJo™ software version 10.7.1 (BD  
157 Bioscience).

158

### 159 **Extraction of the buffy coat and purification of RNA**

160 Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density  
161 gradient centrifugation using Ficoll-Paque (GE Healthcare, Chicago, IL, USA). CD19<sup>+</sup> B-  
162 cells were depleted by magnetic-activated cell sorting (MACS) using human CD19  
163 MicroBeads (Miltenyi, Bergisch-Gladbach, Germany) if CLL cell population exceeded  
164 10% of viable lymphocytes, as determined by flow cytometry, prior to RNA extraction.  
165 3x10<sup>6</sup> PBMC (with or without CD19 depletion) were collected, washed with PBS and  
166 resuspended in 200ul Homo-TG buffer (Maxwell® 16 LEV simplyRNA Purification Kit,  
167 Promega) and stored at -80°C. RNA was extracted on the Maxwell® 16 Instrument  
168 according to manufacturer's protocol and stored at -80°C for further processing.

169

### 170 **mRNA sequencing (mRNA-seq) and data analysis**

171 Bulk RNA-seq was performed on three million PBMCs obtained prior to the second  
172 vaccination (2-dose cohort) and third vaccination (3-dose cohort) and at days 1/2 (D1/2),  
173 7 (D7) and week 4-5 (W4-5) after the vaccination. RNA-seq was conducted on a total of  
174 XX samples with an average sequencing depth of at least 200 million reads per sample.  
175 The Poly-A containing mRNA was purified by poly-T oligo hybridization from 1 mg of total  
176 RNA and cDNA was synthesized using SuperScript III (Invitrogen). Libraries for  
177 sequencing were prepared according to the manufacturer's instructions with TruSeq  
178 Stranded mRNA Library Prep Kit (Illumina, RS-20020595) and paired-end sequencing  
179 was done with a NovaSeq 6000 instrument (Illumina) yielding 200-350 million reads per  
180 sample. The raw data were subjected to QC analyses using the FastQC tool (version  
181 0.11.9) (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). mRNA-seq read  
182 quality control was done using Trimmomatic<sup>29</sup> (version 0.36) and STAR RNA-seq<sup>30</sup>  
183 (version STAR 2.5.4a) using 150 bp paired-end mode was used to align the reads (hg19).  
184 HTSeq<sup>31</sup> (version 0.9.1) was to retrieve the raw counts and subsequently, Bioconductor  
185 package DESeq2<sup>32</sup> in R (<https://www.R-project.org/>) was used to normalize the counts



186 across samples and perform differential expression gene analysis. Additionally, the  
187 RUVSeq<sup>33</sup> package was applied to remove confounding factors. The data were pre-  
188 filtered keeping only genes with at least ten reads in total. The visualization was done  
189 using dplyr (<https://CRAN.R-project.org/package=dplyr>) and ggplot2.<sup>34</sup> The genes with  
190 log<sub>2</sub> fold change >1 or <-1 and adjusted p-value (pAdj) <0.05 corrected for multiple testing  
191 using the Benjamini-Hochberg method were considered significant and then conducted  
192 gene enrichment analysis (GSEA, <https://www.gsea-msigdb.org/gsea/msigdb>). For T- or  
193 B-cell receptor repertoire sequencing analysis, trimmed fastq files from bulk RNA-seq  
194 were aligned against human V, D and J gene sequences using the default settings with  
195 MiXCR.<sup>35,36</sup> CDR3 sequence and the rearranged BCR/TCR genes were identified.

196

### 197 **Statistical analysis**

198 Differential expression gene (DEG) identification used Bioconductor package DESeq2 in  
199 R. P-values were calculated using a paired, two-side Wilcoxon test and adjusted p-value  
200 (pAdj) corrected using the Benjamini–Hochberg method. Genes with log<sub>2</sub> fold change >1  
201 or <-1, pAdj <0.05 and without 0 value from all sample were considered significant. For  
202 significance of each GSEA category, significantly regulated gene sets were evaluated  
203 with the Kolmogorov-Smirnov statistic. A value of \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p$   
204 < 0.0001 was considered statistically significant.

205

### 206 **Data Sharing Statement**

207 The RNA-seq data from this study were deposited under the accession GSE201642 in  
208 the Gene Expression Omnibus (GEO). RNA-seq data of healthy heterologous vaccinated  
209 individuals were obtained under GSE201535.

210

## 211 **Results**

### 212 **Patient characteristics**

213 Patient characteristics are shown in Table 1, Figure 1A and Supplementary Table 1. At  
214 the time of the vaccination, two patients (13%) had treatment-naïve CLL. Seven (47%)  
215 were on treatment without remission (2 frontline, 4 relapse) or with remission (1 relapse).  
216 Six (40%) were off therapy, including four in clinical complete or partial remission (2

217 frontline, 2 relapse) and two on relapse in need of treatment (1 frontline, 1 relapse). Of  
218 the treated patients, four received venetoclax monotherapy and three ibrutinib  
219 monotherapy. Eleven of 15 patients were previously on anti-CD20 monoclonal antibodies  
220 with/without chemotherapy, either more than 12 months (7 patients) or within 12 months  
221 (4 patients) prior to vaccination. Unfavorable prognostic CLL parameters included  $\beta 2M$   
222  $>3.5$  mg/l (2/15), complex karyotype (2/15), trisomy 12 (1/15), unmutated *IGHV* gene  
223 status (13/15), presence of TP53/del(17p) and/or del(11q) (6/15). Median IgG level was  
224 619 mg/dl (range 159-1141), IgM level of 45 mg/dl (range  $<5$ -179) and IgA level of 98  
225 mg/dl (range 12-210). Median ALC (absolute lymphocyte count) was  $5.9/\mu\text{l}$  (range 3.3-  
226 46.7).

227

### 228 **Antibody response**

229 We analyzed anti-spike IgG antibody levels, neutralizing antibody levels and immune  
230 transcriptomes (RNA-seq) on peripheral immune cells prior to the vaccination (referred to  
231 as Day (D) 0 (D0), on days 2 (D2), 7 (D7) and 14 (D14) and weeks 4-5 (W4-5) post  
232 vaccination (Figure 1B). Circulating antibody levels were most closely correlated with  
233 treatment history.<sup>9,37</sup> After 2-dose vaccination, anti-spike (S) IgG was detected in 6/15  
234 (40%) patients, including 2/6 (33%) off-therapy (#210, 212); 2/2 (100%) treatment-naïve  
235 (#211, 213); 1/4 (25%) on active venetoclax (#203); 0/3 (0%) on ibrutinib; 1/4 (25%) on  
236 anti-CD20 of less than 12 months (#209) (Figures. 2A and 3A; Supplementary Table 2).  
237 Following three vaccination doses, 8/15 patients (53%) showed detectable anti-S  
238 antibodies (Figures 2A and 3A; Supplementary Table 2). Several interesting responses  
239 occurred after a three-dose heterologous regimen. Two naïve patients (#203, #209) that  
240 received frontline therapy with acalabrutinib shortly before or after their third BNT162b2  
241 dose retained seroconversion beyond 6 months post treatment. Patient #203 received  
242 frontline treatment with venetoclax monotherapy prior to first ChAdOx1 vaccination,  
243 showed a detectable anti-S IgG response at D14 post second ChAdOx1 dose that was  
244 lost at W4-5 but then restored after a third BNT162b2 dose. Patient #209, who had an  
245 undiagnosed COVID-19 infection prior to receiving first vaccination and stopped  
246 venetoclax+anti-CD20 treatment shortly before the second vaccination, showed an  
247 antibody response after first vaccination and retained detectable antibody levels through



248 subsequent vaccination even with ongoing B-cell depletion in the context of CLL  
249 remission. It is reported that SARS-CoV-2 infection leads to more robust and durable B  
250 and T cell immune responses than COVID-19 vaccination in CLL patients.<sup>38</sup> Two patients  
251 on ibrutinib (#107, 205), who failed humoral response after two homologous ChAdOx1  
252 doses, seroconverted after the third heterologous BNT162b2 dose. Patient #107, who  
253 was in second relapse and on ibrutinib treatment for two years, showed a delayed  
254 seroconversion three months after a temporal pause of ibrutinib, while receiving a third  
255 heterologous BNT162b2 dose. Patient #205, who was on ibrutinib within 6 months,  
256 showed a delayed antibody response to the third heterologous BNT162b2 vaccination.  
257 Results were consistent with the notion that patients with adequate levels of serum  
258 immunoglobulins showed an increased antibody response after third vaccination,  
259 whereas those with very low serum levels of IgA, IgG and IgM, respectively, failed to  
260 seroconvert following vaccination (Supplementary Table 1). Overall, 7/15 of patients  
261 failed to mount a detectable humoral response even after 3-dose vaccination, irrespective  
262 of homologous or heterologous vaccination protocol. These patients were all heavily pre-  
263 treated. Three were on current venetoclax treatment (#103, 104, 201), one presented with  
264 CLL relapse with therapy pending (#106), one on prolonged ibrutinib (#208), and two with  
265 anti-CD20 exposure less than 12 months before vaccination (#105, 206). Development  
266 of neutralizing antibodies was limited to the four patients showing a maximal antibody  
267 response following 2-dose vaccination that was not boosted by 3-dose vaccination (# 210,  
268 211, 212, 213) (Figure 2B; Supplementary Table 2).

269

### 270 **Cellular immune response**

271 Robust T cell responses were detected in 12/15 patients (80%) after 2-dose vaccination  
272 and 14/15 patients (90%) following 3-dose vaccination (Figure 2C; Supplementary Table  
273 3). T-cell response rate was independent of clinical characteristics, intrinsic immune and  
274 treatment status (Figure 3B). All seropositive patients (8/8) as well as 6/7 seronegative  
275 patients developed a T cell mediated IFN- $\gamma$  response. The one seronegative patient  
276 (#104) without a T cell response even after a third heterologous vaccination was on  
277 current venetoclax treatment. One patient (#213), who started frontline therapy with  
278 acalabrutinib shortly before the third heterologous vaccination, lost T cell response.

279 Further analysis of cellular immune cell activation in all patients via flow cytometry  
280 revealed highly variable levels of activated and exhausted T cells, myeloid derived-  
281 suppressor cells (MDSCs), and NK cells was performed but there was no correlation  
282 between these results and response rates detected by IFN- $\gamma$  (Supplementary Table 4).

283

### 284 **Transcriptional immune response**

285 Next, we assessed the vaccine-induced innate immune response and transcriptional  
286 response in PBMCs isolated from 2- and 3-dose vaccination cohorts at days 0 (D0), 2  
287 (D2), 7 (D7) and week 4-5 (W4-5) following vaccination (Figure 1B). The sequencing  
288 depth of 200 million reads per sample permitted an in-depth analysis of early response  
289 immunes and germline alleles induced by the vaccine. Reference cohorts were healthy  
290 individuals receiving heterologous or homologous vaccinations.<sup>17</sup> Samples were available  
291 for eight patients: 3-dose BNT-BNT-ChAd (#103, #104, #106), 2-dose ChAd-ChAd (#201,  
292 #208, #209), 2-dose ChAd-BNT (#206, #212). First, numbers of differentially expressed  
293 genes (DEGs) were measured to examine the immediate response upon vaccination  
294 (Figure 4; Supplementary Figures 1-2). IFN- $\gamma$  enrichment scores for DEGs at D2 were  
295 independent of antibody response. High levels were found both in patients with (#209,  
296 #212) and without (#201, #208) an antibody response (Figure 4A). Cell cycle pathway  
297 enrichment scores for DEGs were highest at D7, significantly higher both as compared to  
298 D2 (Figure 4B) and D0 (Figure 4C). Similarly, higher enrichment in cell cycle pathways  
299 also did not correlate with seroconversion (#106, #201, #208). Patient #104, the one  
300 patient without a T-cell response, showed relatively low enrichment for both IFN- $\gamma$   
301 enrichment scores at D2 and cell cycle pathway enrichment at D7. Patient #206 had a  
302 higher IFN- $\gamma$  score at D7 compared to D2, suggesting delayed immune response. This  
303 patient exhibited a T-cell response and experienced a mild COVID-19 infection during  
304 follow-up, but this was not associated with seroconversion. While the magnitude of  
305 activation varied, activation of interferon-induced genes (*IFI27*, *ISG15*, *CXCL10*, *GBP1*),  
306 JAK/STAT signaling genes including *STAT1*, antiviral pattern recognition receptors  
307 (*DDX58*, *DHX58*) and *OAS* family genes at D2 were qualitatively similar to healthy  
308 controls (Fig. 4D). Induction of *IFI6* and *IFIT* genes were higher in CLL patients compared  
309 to healthy controls. While the transcriptome response varied greatly between individual

310 CLL patients and was independent of the clinical characteristics and treatment status, the  
311 vast majority of CLL patients regardless of antibody response exhibited an early  
312 transcriptome immune response presaging a later sustained T-cell mediated IFN- $\gamma$   
313 immune response.

314

### 315 **Immunoglobulin germline repertoire**

316 Finally, expression profiles of specific germline variable gene classes were interrogated.  
317 First, the range of immunoglobulin heavy chain variable (*IGHV*), light chain (*IGKV*, *IGLV*),  
318 and T cell receptor alpha/beta variable (*TRAV*, *TRBV*) gene usage in the CLL patients  
319 was assessed (Figures 5-6). Final clonotype numbers were more than four-fold lower at  
320 D0 and D7 as compared to vaccinated healthy controls (Figure 5A). A broad range of  
321 germplines in each patient was revealed by a deeper analysis of *IGHV* using  
322 complementarity determining regions (CDR)1 and CDR2 (Figure 5B). We observed  
323 *IGHV3-74*, *IGHV3-30/IGHV3-33*, *IGHV1-18*, *IGHV3-23*, *IGHV3-21* and *IGHV4-59* that are  
324 the basis of neutralizing antibodies identified in SARS-CoV-2 patients.<sup>39-42</sup> In six patients  
325 these clones were specifically increased (#103, #104, #201, #203, #212, #213). Three  
326 antibody responsive patients, including treatment-naïve (#213), on venetoclax (#203),  
327 and off-therapy (#212), showed relatively higher numbers of *IGHV* clones. Because of  
328 transiently diminished B-cells upon active venetoclax treatment, patient #203 had more  
329 *IGHV* clones at D0 and D7 than W4-5 while other antibody responsive patients (#209,  
330 #210, #211) showed low and progressive numbers by recovered B cells. Notably, no B  
331 cell receptor (*BCR*) clones were detected in the antibody non-responder #206, likely due  
332 to completely depleted B cells by CLL treatment. Overall, results illustrate initially low  
333 levels of *BCR* in CLL patients lacking a humoral and neutralizing antibody response  
334 gradually increase upon B-cell reconstitution with effective CLL therapy. In contrast to  
335 *BCR* genes, activation of T Cell Receptor (*TCR*) genes (*TRAV*, *TRBV*) was readily  
336 detected (Figure 6A), consistent with preservation of T cell responses. Several *TRAV* and  
337 *TRBV* genes that are present in COVID-19 convalescent patients<sup>43,44</sup> were induced in the  
338 CLL patients at between D0 and W4-5 (Figure 6B).

339

### 340 **Discussion**

341 In this study, we demonstrate that CLL patients under active surveillance and those that  
342 are treatment-naïve exhibit a superior response to COVID-19 vaccination than patients  
343 on active treatment. While naïve or minimally treated patients showed an expanded  
344 humoral and cellular immune response, the heavily pretreated patients exhibited only T  
345 cell immune responses, even with repeated immune stimulation utilizing a heterologous  
346 vaccination regimen. The value of a third vaccination was most pronounced in patients  
347 who exhibited evidence of a recuperated immune system following effective CLL  
348 treatment. These results coincided with pattern of transcriptional expression of immune  
349 genes and BCR/TCR repertoire.

350 Interrogation of the transcriptional response to vaccination utilizing RNA-seq  
351 highlighted that nearly all CLL patients demonstrated transcriptional activation of early  
352 innate immune response pathways, including interferon-JAK/STAT signaling,<sup>17,25</sup> within  
353 two days, regardless of the antibody response. Interferon-mediated innate immune  
354 response serves as a biomarker and plays a critical role in the immune system to control  
355 viral replication combating SARS-CoV-2 infection.<sup>17,45,46</sup>

356 Skewed IGHV usage, including the appearance of *IGHV1-69*, *IGHV 4-34*, and  
357 *IGHV 3-21*, was observed in the *BCR* repertoire of the CLL patients. Diverse *IGHV* usage  
358 occurs in COVID-19 patients and vaccinated individuals.<sup>17,25</sup> In addition, the final number  
359 of clonotypic B cells detected was much lower in non-IgG responders and even in the  
360 seropositive CLL-patients were lower vaccinated healthy controls. The data is consistent  
361 with increased numbers of SARS-CoV-2 specific IGHV clones correlating with an  
362 improvement of humoral response rate and B-cell reconstitution.

363 Hypogammaglobulinemia in CLL patients results from leukemic cells perturbing  
364 the interaction between T and B cells. Patients with low serum immunoglobulin levels  
365 typically show ineffective humoral responses after both primary and subsequent boosting  
366 doses.<sup>14,23,47</sup> Half of patients with persistent immunodeficiency or B-cell depletion  
367 following initial vaccination remain seronegative after a booster dose.<sup>8,9,14,48</sup> T cell  
368 immunity is essential for viral recognition and clearance and cellular responses can  
369 prevent initial infection and seroconversion.<sup>10,23,48</sup> T cells are especially critical in immune  
370 protection against SARS-CoV-2 in cancer patients, who undergo therapy with B cell  
371 depleting agents, such as anti-CD20 antibody.<sup>49,50</sup> Here we report that CLL patients with

372 diminished numbers of functional CD19+ B cells, a key player in humoral response  
373 against SARS-CoV-2 virus, developed robust T cell immune responses to COVID-19  
374 vaccination.

375         Importantly, we also found a BTKi or BCL2i treatment-dependent effect on the  
376 immune response to COVID-19 vaccine boosters. Vaccine effectiveness is moderated by  
377 the time between treatment completion and vaccination.<sup>8,51</sup> Here, CLL patients treated for  
378 more than five years failed to seroconvert, while patients pretreated with the BTK  
379 inhibitors ibrutinib or acalabrutinib for two years or less seroconverted after 2-3 doses of  
380 a COVID-19 vaccine. Prolonged BTKi treatment predisposes patients towards an  
381 ineffective vaccine immune response because B-cell maturation relies on functional  
382 BTK.<sup>52</sup> Increased serum IgA levels in BTKi-treated CLL patients appears to improve  
383 functional humoral immunity demonstrated by decreased infection susceptibility and  
384 hospitalization rates.<sup>2,52</sup>

385         Protection from severe disease, hospitalization and death by COVID-19  
386 vaccination results from the combination of humoral immunity with a durable cellular  
387 immune memory response. In immunocompromised patients the timing of initial and  
388 booster vaccination should be carefully considered in reference to the underlying disease  
389 status. Remission-inducing therapy resulting in improved immune status and B-cell  
390 reconstitution improves adaptive immunity.<sup>12</sup>

391

### 392 **Limitations of the study**

393 There are several limitations to this study. The study was conducted on volunteers from  
394 a specific geographical area, Munich (Germany), total numbers of CLL patients were  
395 limited, and samples were not available from all patients for all vaccination timepoints for  
396 the RNA-seq studies.

397

### 398 **Acknowledgments**

399 Our gratitude goes to the participants who contributed to this study to advance our  
400 understanding of COVID-19 vaccination. This work used the computational resources of  
401 the NIH HPC Biowulf cluster (<http://hpc.nih.gov>). RNA-sequencing was conducted in the  
402 NIH Intramural Sequencing Center, NISC (<https://www.nisc.nih.gov/contact.htm>).

403           This work was supported by the Intramural Research Program (IRP) of the  
404 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the  
405 Bavarian State Ministry of Science and Art, Special Program for the Promotion of COVID-  
406 19 Research (AKZ H.40001.1.7, to MB).

407

#### 408 **Authorship**

409 Contribution: H.K.L., M.A.H., P.A.F., C.M.W. and L.H. designed the research study;  
410 H.K.L. performed RNA-seq and data analysis; M.A.H and T.T.P. selected the patients,  
411 collected, and curated data; H.K.L, M.A.H., M.B., T.T.P., P.A.F., C.M.W. and L.H.  
412 analyzed results; H.K.L. prepared figures; H.K.L. and T.T.P prepared table; M.A.H., M.B.,  
413 T.T.P., J.W.H., K.M., S.Z., H.V.B., P.G., R.W., L.B. and L.P. prepared samples; H.K.L,  
414 M.A.H., M.B., P.A.F., C.M.W and L.H. wrote manuscript. All authors read and approved  
415 the final version.

416

#### 417 **Disclosure of Conflicts of Interest**

418 M.A.H. received consultancy fees from AstraZeneca. C.M.W. received consultancy fees  
419 from AstraZeneca and BioNTech. The remaining authors declare no conflicts of interests.

420



## 421 **References**

- 422 1. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with  
423 CLL: a multicenter international experience. *Blood*. 2020;136(10):1134-1143.
- 424 2. Scarfo L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and  
425 mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the  
426 European Research Initiative on CLL, and CLL Campus. *Leukemia*. 2020;34(9):2354-  
427 2363.
- 428 3. Roeker LE, Eyre TA, Thompson MC, et al. COVID-19 in patients with CLL:  
429 improved survival outcomes and update on management strategies. *Blood*.  
430 2021;138(18):1768-1773.
- 431 4. Crassini KR, Zhang E, Balendran S, et al. Humoral immune failure defined by  
432 immunoglobulin class and immunoglobulin G subclass deficiency is associated with  
433 shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. *Br J*  
434 *Haematol*. 2018;181(1):97-101.
- 435 5. Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency  
436 and infection risk in 150 patients with chronic lymphocytic leukemia. *Leuk Lymphoma*.  
437 2013;54(1):99-104.
- 438 6. Forconi F, Moss P. Perturbation of the normal immune system in patients with  
439 CLL. *Blood*. 2015;126(5):573-581.
- 440 7. Benjamini O, Rokach L, Itchaki G, et al. Safety and efficacy of the BNT162b  
441 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.  
442 *Haematologica*. 2022;107(3):625-634.
- 443 8. Morawska M. Reasons and consequences of COVID-19 vaccine failure in  
444 patients with chronic lymphocytic leukemia. *Eur J Haematol*. 2022;108(2):91-98.
- 445 9. Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in  
446 patients with chronic lymphocytic leukemia. *Leukemia*. 2021;35(9):2703-2705.
- 447 10. Liebers N, Speer C, Benning L, et al. Humoral and cellular responses after  
448 COVID-19 vaccination in anti-CD20-treated lymphoma patients. *Blood*.  
449 2022;139(1):142-147.
- 450 11. Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-  
451 19 mRNA vaccines in hematologic malignancies patients. *medRxiv*. 2021.

- 452 12. Barriere J, Re D, Peyrade F, Carles M. Current perspectives for SARS-CoV-2  
453 vaccination efficacy improvement in patients with active treatment against cancer. *Eur J*  
454 *Cancer*. 2021;154:66-72.
- 455 13. Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is  
456 significantly less effective in patients with hematologic malignancies. *Am J Hematol*.  
457 2021;96(10):1195-1203.
- 458 14. Herishanu Y, Rahav G, Levi S, et al. Efficacy of a third BNT162b2 mRNA  
459 COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.  
460 *Blood*. 2022;139(5):678-685.
- 461 15. Parry H, Mcllroy G, Bruton R, et al. Antibody responses after first and second  
462 Covid-19 vaccination in patients with chronic lymphocytic leukaemia. *Blood Cancer J*.  
463 2021;11(7):136.
- 464 16. Banki Z, Mateus J, Rossler A, et al. Heterologous ChAdOx1/BNT162b2  
465 vaccination induces stronger immune response than homologous ChAdOx1  
466 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.  
467 *EBioMedicine*. 2022;80:104073.
- 468 17. Lee HK, Go J, Sung H, et al. Heterologous ChAdOx1-BNT162b2 vaccination in  
469 Korean cohort induces robust immune and antibody responses that includes Omicron.  
470 *iScience*. 2022;25(6):104473.
- 471 18. European Medicines Agency ([https://www.ema.europa.eu/en/news/ema-ecdc-](https://www.ema.europa.eu/en/news/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-approach-can-be)  
472 [recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-](https://www.ema.europa.eu/en/news/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-approach-can-be)  
473 [approach-can-be](https://www.ema.europa.eu/en/news/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-approach-can-be))
- 474 19. Azzolini E, Pozzi C, Germagnoli L, et al. mRNA COVID-19 vaccine booster  
475 fosters B- and T-cell responses in immunocompromised patients. *Life Sci Alliance*.  
476 2022;5(6).
- 477 20. Zaleska J, Kwasnik P, Paziewska M, et al. Response to anti-SARS-CoV-2 mRNA  
478 vaccines in multiple myeloma and chronic lymphocytic leukemia patients. *Int J Cancer*.  
479 2022.
- 480 21. Lyski ZL, Kim MS, Xthona Lee D, et al. Immunogenicity of Pfizer mRNA COVID-  
481 19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with  
482 Chronic Lymphocytic Leukemia. *Case Rep Hematol*. 2022;2022:6831640.

- 483 22. Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-  
484 specific T cells associates with rapid viral clearance and mild disease in COVID-19  
485 patients. *Cell Rep.* 2021;34(6):108728.
- 486 23. Marasco V, Carniti C, Guidetti A, et al. T-cell immune response after mRNA  
487 SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in  
488 patients with lymphoid malignancies. *Br J Haematol.* 2022;196(3):548-558.
- 489 24. Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular  
490 immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med.* 2021;218(5).
- 491 25. Lee HK, Knabl L, Moliva JI, et al. mRNA vaccination in octogenarians 15 and 20  
492 months after recovery from COVID-19 elicits robust immune and antibody responses  
493 that include Omicron. *Cell Rep.* 2022;39(2):110680.
- 494 26. Garg I, Sheikh AB, Pal S, Shekhar R. Mix-and-Match COVID-19 Vaccinations  
495 (Heterologous Boost): A Review. *Infect Dis Rep.* 2022;14(4):537-546.
- 496 27. Thomson T, Prendecki M, Gleeson S, et al. Immune responses following 3rd and  
497 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant  
498 recipients. *EClinicalMedicine.* 2022;53:101642.
- 499 28. Haselmann V, Ozcurumez MK, Klawonn F, et al. Results of the first pilot external  
500 quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing. *Clin Chem*  
501 *Lab Med.* 2020;58(12):2121-2130.
- 502 29. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina  
503 sequence data. *Bioinformatics.* 2014;30(15):2114-2120.
- 504 30. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq  
505 aligner. *Bioinformatics.* 2013;29(1):15-21.
- 506 31. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-  
507 throughput sequencing data. *Bioinformatics.* 2015;31(2):166-169.
- 508 32. Love MI, Huber W, Anders S. Moderated estimation of fold change and  
509 dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550.
- 510 33. Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using  
511 factor analysis of control genes or samples. *Nat Biotechnol.* 2014;32(9):896-902.
- 512 34. Wickham H. Ggplot2 : elegant graphics for data analysis. New York: Springer;  
513 2009.

- 514 35. Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for  
515 comprehensive adaptive immunity profiling. *Nat Methods*. 2015;12(5):380-381.
- 516 36. Bolotin DA, Poslavsky S, Davydov AN, et al. Antigen receptor repertoire profiling  
517 from RNA-seq data. *Nat Biotechnol*. 2017;35(10):908-911.
- 518 37. Diamantopoulos PT, Stafylidis C, Vlachopoulou D, et al. Safety and  
519 immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic  
520 lymphocytic leukemia: a prospective study. *Ther Adv Hematol*.  
521 2022;13:20406207221090150.
- 522 38. Blixt L, Bogdanovic G, Buggert M, et al. Covid-19 in patients with chronic  
523 lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in  
524 consecutive patients. *Leukemia*. 2022;36(2):476-481.
- 525 39. Xiang H, Zhao Y, Li X, et al. Landscapes and dynamic diversifications of B-cell  
526 receptor repertoires in COVID-19 patients. *Hum Immunol*. 2022;83(2):119-129.
- 527 40. Andreano E, Paciello I, Piccini G, et al. Hybrid immunity improves B cells and  
528 antibodies against SARS-CoV-2 variants. *Nature*. 2021;600(7889):530-535.
- 529 41. Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the  
530 recovery stage by single-cell sequencing. *Cell Discov*. 2020;6:31.
- 531 42. He B, Liu S, Wang Y, et al. Rapid isolation and immune profiling of SARS-CoV-2  
532 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. *Signal  
533 Transduct Target Ther*. 2021;6(1):195.
- 534 43. Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological  
535 responses in patients with COVID-19. *Nat Immunol*. 2020;21(9):1107-1118.
- 536 44. Luo L, Liang W, Pang J, et al. Dynamics of TCR repertoire and T cell function in  
537 COVID-19 convalescent individuals. *Cell Discov*. 2021;7(1):89.
- 538 45. Huang L, Shi Y, Gong B, et al. Dynamic blood single-cell immune responses in  
539 patients with COVID-19. *Signal Transduct Target Ther*. 2021;6(1):110.
- 540 46. Knabl L, Lee HK, Wieser M, et al. BNT162b2 vaccination enhances interferon-  
541 JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-  
542 CoV-2 Beta variant. *Commun Med (Lond)*. 2022;2(1).


- 543 47. Lyski ZL, Kim MS, Xthona Lee D, et al. Cellular and humoral immune response  
544 to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. *Blood*  
545 *Adv.* 2022;6(4):1207-1211.
- 546 48. Re D, Seitz-Polski B, Brglez V, et al. Humoral and cellular responses after a third  
547 dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. *Nat*  
548 *Commun.* 2022;13(1):864.
- 549 49. Riise J, Meyer S, Blaas I, et al. Rituximab-treated patients with lymphoma  
550 develop strong CD8 T-cell responses following COVID-19 vaccination. *Br J Haematol.*  
551 2022;197(6):697-708.
- 552 50. Blixt L, Wullimann D, Aleman S, et al. T-cell immune responses following  
553 vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic  
554 lymphocytic leukemia: results from a prospective open-label clinical trial.  
555 *Haematologica.* 2022;107(4):1000-1003.
- 556 51. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19  
557 vaccine in patients with chronic lymphocytic leukemia. *Blood.* 2021;137(23):3165-3173.
- 558 52. Palma M, Mulder TA, Osterborg A. BTK Inhibitors in Chronic Lymphocytic  
559 Leukemia: Biological Activity and Immune Effects. *Front Immunol.* 2021;12:686768.  
560  
561

562 **Table 1. Characteristics of CLL study population.**

N	15
<b>Age (years), median (range)</b>	69 (59-82)
<b>Gender</b>	
Female	6 (40%)
Male	9 (60%)
<b>Race</b>	
Caucasian	15 (100%)
<b>COVID-19 vaccination</b>	
BNT-BNT-ChAd	4 (27%)
ChAd-BNT-BNT	2 (13%)
ChAd-ChAd-BNT	9 (60%)
<b>Disease status</b>	
Naive	2 (13%)
Frontline active	2 (13%)
Relapse active	3 (20%)
Relapse in need of treatment	2 (13%)
In remission	5 (33%)
<b>Prior treatment (CT/CIT/IT)</b>	
< 3	4 (27%)
≥ 3	7 (47%)
<b>Current treatment</b>	
BTK inhibitor	3 (20%)
Bcl2 inhibitor	4 (27%)
Off-therapy	6 (40%)
W&W	2 (13%)
<b>IGHV status</b>	
Mutated	2 (13%)
<b>Risk factors</b>	
Trisomy 12	1 (7%)
17p deletion/T53 mutation	5 (33%)
11q deletion	2 (13%)
Complex karyotype	2 (13%)
High $\beta$ M2	2 (13%)
<b>Serum IgG level (mg/dl), median (range)</b>	619 (159-1141)
<b>Serum IgM level (mg/dl), median (range)</b>	45 (<5-179)
<b>Serum IgA level (mg/dl), median (range)</b>	98 (10-210)
<b>B lymphocytes (%), median (range)</b>	7.2 (0-84.6)




563



564

565


566 **Figure 1. Study population and design.** (A) CLL patient groups by treatment (naïve  
567 (n=2), treatment active (n=7), off-treatment (n=6)) and by drugs (BTKi (n=3), Bcl2i (n=4),  
568 anti-CD20 for less than 12 months (n=4), anti-CD20 for more than 12 months (n=2)).  
569 Mean distances between dose 1 and 2, and dose 2 and 3 were 82 and 132 days,  
570 respectively. (B) Blood samples were collected prior to the vaccination (D0) and at days  
571 2 (D2), 7 (D7) and 14 (D14) and weeks 4-5 (W4-5) post second and third vaccination as  
572 indicated by the colored circles.



573


574

575 **Figure 2. Humoral and T cell immune responses following second dose and**  
576 **booster vaccination.** (A) Plasma IgG antibody binding against the S1 domain of SARS-  
577 CoV-2 spike in CLL patients. (B) Neutralizing antibody response to SARS-CoV-2 RBD  
578 (spike). (C) IFN- $\gamma$  levels secreted from lymphocytes by stimulation of a SARS-CoV-2  
579 peptide cocktail.



580


581 **Figure 3. Anti-spike mediated T cell response in CLL patients.** (A) Seroconversion  
 582 rate. (B) T cell response rate after 2-dose and 3-dose vaccines in patient subgroups  
 583 based on clinical parameters and treatment status. Y-axis presents the proportions (%) of  
 584 CLL patients. S, standard of active level, IgG: 552 mg/dl, IgM: 33 mg/dl, IgA: 69 mg/dl.



585


586

587 **Figure 4. Immune transcriptomes following vaccination.** (A-C) Interferon-regulated  
 588 genes are induced upon vaccination. Genes expressed at significantly higher levels at  
 589 days 2 and 7, as compared to day 0 were significantly enriched in Hallmark gene sets. X-  
 590 axis denotes statistical significance as measured by minus logarithm of FDR q-values. Y-  
 591 axis denotes ranked terms by q-values. (D) Heatmaps show log<sub>2</sub> FC of IFN- $\gamma$  response  
 592 genes (top) and G2M target genes (bottom) significantly regulated between day0 and  
 593 day2, day2 and day7, and day0 and day7.



594

595 **Figure 5. SARS-CoV-2 B-cell memory.** (A) Bar graphs were shown the number of  
 596 clonotypes in each patient after the vaccination. (B) Pie charts for IGHV show the  
 597 distribution of antibody sequences of individuals prior to the vaccination and after 7 days  
 598 and 4~5 weeks. The number of sequences analyzed for individual are shown in the inner  
 599 circle. Sizes of pie slices are proportional to the number of clonally related sequences.  
 600 Persisting clones (same IGV genes) in both time points are shown as colored slices.  
 601 White indicates sequences not overlapped between individuals.



602

603 **Figure 6. SARS-CoV-2 T-cell memory.** (A) Bar graphs were shown the number of  
604 clonotypes in each patient after the vaccination. (B) Box plots show the induction fold of  
605 variable (V) gene usage from TCR $\alpha$  and TCR $\beta$  chain.

606